← back to search

Thomas A Prohaska

Ionis Pharmaceuticals (United States) · US
Area of research
Immunology · Cardiology and Cardiovascular Medicine
Research interest
Research interests include Lipid metabolism and disorders, Atherosclerosis and Cardiovascular Diseases, Diabetes, Cardiovascular Risks, and Lipoproteins, and T-cell and B-cell Immunology.
h-index
14
citations
1,656
works
28
NIH funding
primary concept
email

Recent publications

Targeting <i>APOC3</i> with Olezarsen in Moderate Hypertriglyceridemia
New England Journal of Medicine 2025cited by 47position: middledoi
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk
New England Journal of Medicine 2025cited by 30position: middledoi
Particle uptake by macrophages triggers bifurcated transcriptional pathways that differentially regulate inflammation and lysosomal gene expression
Immunity 2025cited by 19position: middledoi
Volanesorsen to Prevent Acute Pancreatitis in Hypertriglyceridemia
New England Journal of Medicine 2024cited by 77position: middledoi
APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia
Journal of clinical lipidology 2023cited by 45position: firstdoi
RANK ligand converts the NCoR/HDAC3 co-repressor to a PGC1β- and RNA-dependent co-activator of osteoclast gene expression
Molecular Cell 2023cited by 21position: middledoi
Systematic analysis of naturally occurring insertions and deletions that alter transcription factor spacing identifies tolerant and sensitive transcription factor pairs
eLife 2022cited by 23position: middledoi
Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice
Nature 2018cited by 513position: middledoi
B-1b Cells Secrete Atheroprotective IgM and Attenuate Atherosclerosis
Circulation Research 2015cited by 141position: middledoi
Circulating microparticles carry oxidation-specific epitopes and are recognized by natural IgM antibodies
Journal of Lipid Research 2014cited by 110position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Sotirios Tsimikas · Vanderbilt University Medical Center6 papers (2014–2025)Joseph L. Witztum · Optimum Therapeutics (United States)5 papers (2014–2024)Veronica J. Alexander · Ionis Pharmaceuticals (United States)3 papers (2023–2025)Christopher K. Glass · University of California San Diego2 papers (2018–2022)Christoph J. Binder · Federal Agency for Scientific Organizations2 papers (2014–2018)Ewa Karwatowska‐Prokopczuk · Ionis Pharmaceuticals (United States)2 papers (2023–2024)Ayelet Gonen · University of California San Diego2 papers (2015–2018)Cody J. Diehl · University of Arkansas at Fayetteville1 papers (2018–2018)Chantel McSkimming · Carter Center1 papers (2015–2015)Karen Bowden · University of California, San Diego1 papers (2018–2018)Klaus Ley · University of California San Diego1 papers (2018–2018)Jeffrey G. MacDonald · Southwestern Medical Center1 papers (2018–2018)Erica L. Goodrich · Harvard University1 papers (2025–2025)Jenhan Tao · University of California San Diego1 papers (2022–2022)Marc S. Sabatine · Smart Material (Germany)1 papers (2025–2025)Rick Z. Li · University of California System1 papers (2022–2022)Robert A. Hegele · Western University1 papers (2024–2024)Sam Rosenfeld · University of Virginia1 papers (2015–2015)Yury I. Miller · University of San Diego1 papers (2018–2018)Timothy P. Bender · University of Virginia1 papers (2015–2015)